A Eggert1, R Ho, N Ikegaki, X G Liu, G M Brodeur. 1. Division of Oncology, The Children's Hospital of Philadelphia and Department of Pediatrics, The University of Pennsylvania, Philadelphia, Pennsylvania 19104-4318, USA.
Abstract
BACKGROUND: Expression of the neurotrophin receptor TrkA is associated with a favorable prognosis in neuroblastoma (NB) and promotes growth inhibition and neuronal differentiation. Aggressive, MYCN-amplified NB tumors express little or no TrkA mRNA, suggesting that MYCN overexpression may inhibit TrkA expression. PROCEDURE: To study the interactions of TrkA expression and MYCN amplification in NB, we stably expressed the TrkA receptor in the MYCN single copy cell lines SH-SY5Y and NB69 as well as in the MYCN amplified cell lines CHP134 and IMR5. RESULTS: All four transfected cell lines demonstrated high TrkA expression and similar activation of the TrkA receptor and of mitogen-activated protein kinases as well as induction of immediate-early genes in response to nerve growth factor (NGF). Introduction of TrkA restored NGF responsiveness of SH-SY5Y and NB69 cells, as demonstrated by morphologic differentiation, growth inhibition, and enhanced survival in serum-free medium. However, no morphologic, growth, or survival responses to NGF were detected in MYCN-amplified CHP134 and IMR5 TrkA transfectants. CONCLUSIONS: Thus, transfection of TrkA into MYCN amplified NB cell lines only partly restored the TrkA/NGF signaling pathway, suggesting additional inhibitory effects of MYCN overexpression on TrkA signaling. Copyright 2000 Wiley-Liss, Inc.
BACKGROUND: Expression of the neurotrophin receptor TrkA is associated with a favorable prognosis in neuroblastoma (NB) and promotes growth inhibition and neuronal differentiation. Aggressive, MYCN-amplified NB tumors express little or no TrkA mRNA, suggesting that MYCN overexpression may inhibit TrkA expression. PROCEDURE: To study the interactions of TrkA expression and MYCN amplification in NB, we stably expressed the TrkA receptor in the MYCN single copy cell lines SH-SY5Y and NB69 as well as in the MYCN amplified cell lines CHP134 and IMR5. RESULTS: All four transfected cell lines demonstrated high TrkA expression and similar activation of the TrkA receptor and of mitogen-activated protein kinases as well as induction of immediate-early genes in response to nerve growth factor (NGF). Introduction of TrkA restored NGF responsiveness of SH-SY5Y and NB69 cells, as demonstrated by morphologic differentiation, growth inhibition, and enhanced survival in serum-free medium. However, no morphologic, growth, or survival responses to NGF were detected in MYCN-amplified CHP134 and IMR5 TrkA transfectants. CONCLUSIONS: Thus, transfection of TrkA into MYCN amplified NB cell lines only partly restored the TrkA/NGF signaling pathway, suggesting additional inhibitory effects of MYCN overexpression on TrkA signaling. Copyright 2000 Wiley-Liss, Inc.
Authors: Ruth Ho; Jane E Minturn; Anisha M Simpson; Radhika Iyer; Jennifer E Light; Audrey E Evans; Garrett M Brodeur Journal: Cancer Lett Date: 2011-03-17 Impact factor: 8.679
Authors: Ramesh Narayanan; Muralimohan Yepuru; Christopher C Coss; Zhongzhi Wu; Matthew N Bauler; Christina M Barrett; Michael L Mohler; Yun Wang; Juhyun Kim; Linda M Snyder; Yali He; Nelson Levy; Duane D Miller; James T Dalton Journal: PLoS One Date: 2013-12-26 Impact factor: 3.240
Authors: Merel A W Oortveld; Shivakumar Keerthikumar; Martin Oti; Bonnie Nijhof; Ana Clara Fernandes; Korinna Kochinke; Anna Castells-Nobau; Eva van Engelen; Thijs Ellenkamp; Lilian Eshuis; Anne Galy; Hans van Bokhoven; Bianca Habermann; Han G Brunner; Christiane Zweier; Patrik Verstreken; Martijn A Huynen; Annette Schenck Journal: PLoS Genet Date: 2013-10-31 Impact factor: 5.917